ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2044

Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies

Ivan Arias de la Rosa1, Patricia Ruiz-Limon1, Carlos Perez-Sanchez2, Maria Carmen Abalos-Aguilera1, Yolanda Jiménez-Gómez2, Irene Cecchi3, Rafaela Ortega-Castro2, Miguel Angel Caracuel-Ruiz4, Jerusalem Calvo-Gutierrez2, Alejandro Escudero-Contreras1, Eduardo Collantes-Estévez2, Chary Lopez-Pedrera4 and Nuria Barbarroja2, 1Rheumatology Service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 2Rheumatology service, IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Center of Research of Immunopathology and Rare Diseases- Coordinating Center of Piemonte and Valle d’Aosta Network for Rare Diseases, Department of Clinical and Biological Sciences, University of Turin, Italy, Turin, Italy, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Biologic drugs, Epigenetics, MicroRNA, neutrophils and rheumatoid arthritis (RA)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Rheumatoid Arthritis – Etiology and Pathogenesis Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Neutrophils are the most abundant cells in synovial fluid, having all the features of activated cells in rheumatoid arthritis (RA), including prolonged cell survival, increased migratory capacity and the ability to produce high levels of inflammatory mediators. MicroRNAs (miRNA) have recently emerged as a new class of modulators of gene expression, regulating inflammation, degradation of extracellular matrix and invasive behavior of the resident cells in RA. Purpose: 1) to investigate the miRNA expression pattern in rheumatoid arthritis (RA) neutrophils and its contribution to their pathogenic profile and 2) to analyze the effect of specific autoantibodies or inflammatory components and its modulation by biological therapies.

Methods: Neutrophils were isolated from peripheral blood and paired synovial fluid samples of 40 RA-patients and 40 healthy donors. A microRNA array was performed using nCounter technology. Healthy-neutrophils were treated in vitro with antibodies to citrullinated protein antigens (ACPAs) isolated from RA patients and TNF-a or IL-6. In vitro treatments of RA-neutrophils with tocilizumab(TCZ) or infliximab(IFX) was carried out. Transfections with the pre-miRNAs miR-223, miR-126 and miR-148 were performed in RA neutrophils. DICER silencing using lentiviral transfection in neutrophils was further carried out.

Results: RA-neutrophils showed a global downregulation of miRNAs and genes involved in miRNA biogenesis, alongside with an upregulation of mRNA targets related to survival, migration and inflammation. Decreased levels of miRNAs and DICER correlated with autoimmunity, inflammation and disease activity. ACPAs and TNF-a decreased the expression of numerous miRNAs and their biogenesis-related genes, and increased their mRNA targets. IFX reversed those effects. Transfections with pre-miRNAs-223, -126 and -148a specifically modulated genes regulating inflammation, survival and migration. DICER depletion influenced the neutrophils’ inflammatory profile.

Conclusion: 1) RA-neutrophils exhibit a global low abundance of miRNAs induced by autoantibodies and inflammatory markers, and responsible for their pathogenic activation. 2)miRNA biogenesis is significantly impaired in RA-neutrophils and further associated with a deeper downregulation of miRNAs related to inflammation, migration and survival of synovial neutrophils. 3) Biological therapies such as anti-TNF-a restore miRNA levels, minimizing the inflammatory profile of neutrophils. Supported by the Minister of Health (ISCIII, CP15/0158, PI17/01316, PI15/01333, RIER RD16/0012/0015) cofinanced with FEDER funds.


Disclosure: I. Arias de la Rosa, None; P. Ruiz-Limon, None; C. Perez-Sanchez, None; M. C. Abalos-Aguilera, None; Y. Jiménez-Gómez, None; I. Cecchi, None; R. Ortega-Castro, None; M. A. Caracuel-Ruiz, None; J. Calvo-Gutierrez, None; A. Escudero-Contreras, None; E. Collantes-Estévez, None; C. Lopez-Pedrera, None; N. Barbarroja, None.

To cite this abstract in AMA style:

Arias de la Rosa I, Ruiz-Limon P, Perez-Sanchez C, Abalos-Aguilera MC, Jiménez-Gómez Y, Cecchi I, Ortega-Castro R, Caracuel-Ruiz MA, Calvo-Gutierrez J, Escudero-Contreras A, Collantes-Estévez E, Lopez-Pedrera C, Barbarroja N. Impaired microRNA Processing in Neutrophils from Rheumatoid Arthritis Patients Confers Their Pathogenic Profile. Modulation By Biological Therapies [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/impaired-microrna-processing-in-neutrophils-from-rheumatoid-arthritis-patients-confers-their-pathogenic-profile-modulation-by-biological-therapies/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impaired-microrna-processing-in-neutrophils-from-rheumatoid-arthritis-patients-confers-their-pathogenic-profile-modulation-by-biological-therapies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology